Viking Therapeutics (VKTX) Given a $23.00 Price Target at Roth Capital

Viking Therapeutics (NASDAQ:VKTX) received a $23.00 price target from Roth Capital in a research report issued on Friday. The firm currently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price target indicates a potential upside of 86.54% from the company’s current price.

Several other equities analysts have also recently issued reports on VKTX. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Viking Therapeutics in a research note on Thursday. Maxim Group reiterated a “buy” rating and issued a $28.00 target price on shares of Viking Therapeutics in a research note on Thursday. SunTrust Banks assumed coverage on shares of Viking Therapeutics in a research note on Friday, July 20th. They issued a “buy” rating and a $14.00 target price for the company. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a research note on Friday, August 10th. Finally, BidaskClub upgraded shares of Viking Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Viking Therapeutics has an average rating of “Buy” and an average target price of $28.00.

VKTX opened at $12.33 on Friday. Viking Therapeutics has a 1 year low of $2.24 and a 1 year high of $24.00.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Friday, November 9th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. Analysts forecast that Viking Therapeutics will post -0.44 EPS for the current fiscal year.

In related news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the business’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total value of $5,034,171.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 3.90% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC purchased a new stake in Viking Therapeutics in the 3rd quarter worth $125,858,000. American International Group Inc. increased its holdings in Viking Therapeutics by 21.3% in the 3rd quarter. American International Group Inc. now owns 34,403 shares of the biotechnology company’s stock worth $599,000 after acquiring an additional 6,036 shares in the last quarter. BlackRock Inc. increased its holdings in Viking Therapeutics by 14.0% in the 3rd quarter. BlackRock Inc. now owns 3,349,901 shares of the biotechnology company’s stock worth $58,355,000 after acquiring an additional 411,256 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Viking Therapeutics by 11.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 385,484 shares of the biotechnology company’s stock worth $6,714,000 after acquiring an additional 39,455 shares in the last quarter. Finally, Eagle Asset Management Inc. increased its holdings in Viking Therapeutics by 68.1% in the 3rd quarter. Eagle Asset Management Inc. now owns 130,987 shares of the biotechnology company’s stock worth $2,281,000 after acquiring an additional 53,076 shares in the last quarter. 53.56% of the stock is owned by institutional investors.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

See Also: How to Use a Moving Average for TradingĀ 

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply